GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug
GlaxoSmithKline’s R&D head Hal Barron has spent his four years on the job taking swing after swing to rejuvenate the drug giant’s pipeline after years of inertia. One of Barron’s biggest swings has now blown up in his face after a key cancer drug went down in flames in the clinic.
GSK and Merck KGaA have ended their $4 billion collaboration on bintrafusp alfa, a once-promising cancer drug and the crown jewel of Barron’s pipeline rebuild efforts that has endured a spate of failures in recent months, the companies said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.